Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
With
Bristol-Myers Squibb
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient with mild or moderate hypertension defined with arterial diastolic pressure (PAD) at sit position between 90 mmHg and 110 mmHg and arterial systolic pressure (PAS) at sit position between 140 mmHg and 180 mmHg.
Patient diagnosed after 3 consultations within 2 months who has never been under treatment and responding to the required conditions for hypertension treatment with irbesartan. This patient must has been under proper but insufficient hygieno dietetic diet
Patient who has been under a none satisfied antihypertensive treatment, and for whom this treatment was stopped at least 2 weeks prior to inclusion.
Patient with a laboratory analysis (urinary sediment- Na -K- creatinine, total cholesterol) and ECG during the month prior to inclusion.
You may not be if
Severe Hypertension defined by PAS \> 180mmHg and/or PAD \> 110 mmHg.
Isolated systolic Hypertension
Secondary Hypertension
Arterial stenosis on unique kidney - arterial bilateral kidney stenosis
Non-surgically sterilized women or non-menopaused women.
Confirmed sodic depletion.
Hypersensitivity to Irbesartan.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | APROVE : Irbesartan in Hypertension
